NIH Awards $15 million to Wake Forest School of Medicine for Alzheimer’s Research

August 12, 2021

The National Institute of Aging (NIA), part of the National Institutes of Health, has awarded Wake Forest School of Medicine $15.2 million over five years in support of its research center for Alzheimer’s disease

Established in 2016 with a multimillion-dollar NIA grant, the Alzheimer’s Disease Research Center (ADRC) at Wake Forest School of Medicine is one of only 31 NIA-funded research centers in the country working to translate research advances into improved diagnosis and care for people with the disease, as well as working to find a treatment or ways to prevent Alzheimer's and other types of dementia. 

“Currently there aren’t therapies that effectively prevent or treat the symptoms of Alzheimer’s,” said Suzanne Craft, Ph.D., professor of gerontology and geriatric medicine at Wake Forest School of Medicine and director of its ADRC. 

“Our primary focus will be on finding ways to prevent the disease by identifying it at the very earliest stages when interventions could likely make the biggest difference. We also hope to learn more about how common medical conditions, such as diabetes and high blood pressure, can increase the risk for Alzheimer’s, and how better addressing those conditions may prevent or delay its development.”

Metabolic and vascular disorders are powerful modifiable factors that may contribute to the transitions from normal aging to mild cognitive impairment and Alzheimer’s, Craft said. Such disorders are epidemic in the Southeast; more than 70% of adults over the age of 50 in the region have prediabetes, diabetes or hypertension. These disorders increase the risk of cognitive impairment and dementia through complex interactions that are poorly understood.  

Some of the research already underway at the medical school’s center includes studying special diet and nutrition interventions, such as a modified ketogenic diet as a potential treatment for mild cognitive impairment, and using specific blood pressure and diabetes medications that not only treat those conditions but seem to have an impact on the brain that may prevent Alzheimer’s from developing as quickly, Craft said.

Another area of focus is to understand the role health disparities and social determinants play in influencing the risk for Alzheimer’s by engaging people from underrepresented groups and rural areas who are twice as likely to develop dementia, and have high rates of diabetes and vascular disease. 

In addition, Craft said the center will develop educational programs about Alzheimer’s and dementia for health care professionals, patients and their family members, as well as the community at large.

“Using precision medicine, we hope to be able to identify the predictors of dementia and Alzheimer’s and by doing so, prevent or delay the disease and optimize healthy brain aging,” Craft said. 

Associate directors of the ADRC at Wake Forest School of Medicine are Jeff D. Williamson, M.D., professor and section chief of gerontology and geriatric medicine, and Laura Baker, Ph.D., professor of gerontology and geriatric medicine.

The ADRC at Wake Forest School of Medicine is funded by NIH grant P30AG072947.

 
Media Contact

Marguerite Beck, marbeck@wakehealth.edu336-716-6841